Shire Pharmaceuticals Group Plc
Shire Receives European Approval for INTUNIV®? (Guanfacine Hydrochloride Prolonged Release Tablets) as a Non-stimulant ADHD Treatment for Children and Adolescents
Zug, Switzerland (ots/PRNewswire) - The first selective alpha-2A adrenergic receptor agonist licensed for the treatment of ADHD in the EU Shire today announced that the European Commission granted Marketing Authorisation for once-daily, non-stimulant INTUNIV(R) (guanfacine hydrochloride prolonged release ...